However, upon initiation of ICB and the first SBRT (August/September 2015), patient 2 showed an increase in Ki67+ (i.e., activated) CD8+ T cells and of Ki67+ PD-1+ CD8+ T cells in the blood, which was still detected several months later (May 2016) despite tumor progression. Here, CD8A is linked to neoplasm.